Compare BWFG & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWFG | SIGA |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.5M | 341.0M |
| IPO Year | 2014 | 2016 |
| Metric | BWFG | SIGA |
|---|---|---|
| Price | $51.36 | $4.26 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | 31.4K | ★ 430.1K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | 1.52% | ★ 13.24% |
| EPS Growth | ★ 261.79 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $2,826,000.00 | N/A |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $6.21 | $224.81 |
| P/E Ratio | $35.94 | ★ N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $33.26 | $4.10 |
| 52 Week High | $53.86 | $9.62 |
| Indicator | BWFG | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 34.72 |
| Support Level | $45.40 | N/A |
| Resistance Level | $53.67 | $4.86 |
| Average True Range (ATR) | 1.14 | 0.18 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 38.80 | 19.39 |
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.